10x Genomics, Inc.

LSE:0A88 Stock Report

Market Cap: US$1.8b

10x Genomics Valuation

Is 0A88 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A88 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A88's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A88's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A88?

Key metric: As 0A88 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A88. This is calculated by dividing 0A88's market cap by their current revenue.
What is 0A88's PS Ratio?
PS Ratio2.8x
SalesUS$629.74m
Market CapUS$1.78b

Price to Sales Ratio vs Peers

How does 0A88's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A88 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.9x
ONT Oxford Nanopore Technologies
7.7x22.2%UK£1.3b
ERGO Ergomed
4.6x8.8%UK£701.1m
MXCT MaxCyte
9.5x21.3%UK£345.6m
HVO hVIVO
2x4.1%UK£132.7m
0A88 10x Genomics
2.8x5.5%US$1.8b

Price-To-Sales vs Peers: 0A88 is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (6.4x).

Price to Sales Ratio vs Industry

How does 0A88's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
0A88 2.8xIndustry Avg. 4.3xNo. of Companies7PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A88 is good value based on its Price-To-Sales Ratio (2.8x) compared to the European Life Sciences industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is 0A88's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A88 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: 0A88 is good value based on its Price-To-Sales Ratio (2.8x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A88 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.72
US$20.29
+37.8%
20.3%US$30.00US$14.00n/a14
Dec ’25US$15.84
US$20.29
+28.1%
20.3%US$30.00US$14.00n/a14
Nov ’25US$16.19
US$20.29
+25.3%
20.3%US$30.00US$14.00n/a14
Oct ’25US$21.60
US$26.77
+23.9%
27.8%US$46.00US$16.00n/a15
Sep ’25US$23.04
US$26.69
+15.9%
27.7%US$46.00US$16.00n/a13
Aug ’25US$19.75
US$28.54
+44.5%
35.3%US$50.00US$16.00n/a13
Jul ’25US$18.48
US$39.62
+114.4%
28.0%US$55.00US$24.00n/a13
Jun ’25US$22.27
US$41.14
+84.8%
22.1%US$55.00US$26.00n/a14
May ’25US$26.76
US$40.38
+50.9%
22.8%US$55.00US$26.00n/a14
Apr ’25US$37.83
US$57.79
+52.8%
15.7%US$70.00US$30.00n/a14
Mar ’25US$46.34
US$57.79
+24.7%
15.7%US$70.00US$30.00n/a14
Feb ’25US$43.29
US$58.86
+36.0%
18.2%US$70.00US$30.00n/a14
Jan ’25US$55.87
US$56.50
+1.1%
18.4%US$70.00US$30.00n/a14
Dec ’24US$45.26
US$54.83
+21.2%
22.8%US$70.00US$30.00US$15.8412
Nov ’24US$34.04
US$60.33
+77.3%
21.0%US$75.00US$30.00US$16.1912
Oct ’24US$41.04
US$61.17
+49.1%
21.2%US$75.00US$30.00US$21.6012
Sep ’24US$54.03
US$62.75
+16.1%
19.6%US$75.00US$30.00US$23.0412
Aug ’24US$61.96
US$59.92
-3.3%
19.6%US$68.00US$30.00US$19.7512
Jul ’24US$57.08
US$58.50
+2.5%
21.6%US$68.00US$25.00US$18.4812
Jun ’24US$52.49
US$58.50
+11.5%
21.6%US$68.00US$25.00US$22.2712
May ’24US$50.90
US$54.55
+7.2%
23.3%US$65.00US$25.00US$26.7611
Apr ’24US$54.43
US$53.73
-1.3%
23.4%US$65.00US$25.00US$37.8311
Mar ’24US$46.93
US$52.60
+12.1%
24.0%US$65.00US$25.00US$46.3410
Feb ’24US$45.67
US$49.67
+8.7%
26.8%US$65.00US$25.00US$43.299
Jan ’24US$36.03
US$49.67
+37.9%
26.8%US$65.00US$25.00US$55.879
Dec ’23US$39.07
US$49.63
+27.0%
28.4%US$65.00US$25.00US$45.268

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 08:56
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

10x Genomics, Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Luke SergottBarclays
Michael RyskinBofA Global Research